Zentalis Pharmaceuticals, Inc. Annual Net Income (Loss) Attributable to Parent in USD from 2019 to 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Zentalis Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2019 to 2023.
  • Zentalis Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was -$88.3M, a 21.6% increase year-over-year.
  • Zentalis Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$195M, a 31.7% increase year-over-year.
  • Zentalis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$292M, a 23.4% decline from 2022.
  • Zentalis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$237M, a 49.2% decline from 2021.
  • Zentalis Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$159M, a 34.7% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$292M -$55.4M -23.4% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-27
2022 -$237M -$78.1M -49.2% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-27
2021 -$159M -$40.9M -34.7% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-27
2020 -$118M -$72.2M -158% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-01
2019 -$45.7M Jan 1, 2019 Dec 31, 2019 10-K 2022-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.